ZA200105543B - Improved saponin adjuvant compositions and methods relating thereto. - Google Patents
Improved saponin adjuvant compositions and methods relating thereto. Download PDFInfo
- Publication number
- ZA200105543B ZA200105543B ZA200105543A ZA200105543A ZA200105543B ZA 200105543 B ZA200105543 B ZA 200105543B ZA 200105543 A ZA200105543 A ZA 200105543A ZA 200105543 A ZA200105543 A ZA 200105543A ZA 200105543 B ZA200105543 B ZA 200105543B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition according
- dextran
- adjuvant
- composition
- ionic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000002671 adjuvant Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 10
- 229930182490 saponin Natural products 0.000 title claims description 21
- 150000007949 saponins Chemical class 0.000 title claims description 20
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims description 18
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 34
- 230000002163 immunogen Effects 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 229920002307 Dextran Polymers 0.000 claims abstract description 21
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 230000028993 immune response Effects 0.000 claims abstract description 16
- 229960003983 diphtheria toxoid Drugs 0.000 claims abstract description 10
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 15
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 15
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 15
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 6
- 229920002521 macromolecule Polymers 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 abstract description 8
- 230000001850 reproductive effect Effects 0.000 abstract description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 16
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- -1 Quil A saponins Chemical class 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007758 mating behavior Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP8073A AUPP807399A0 (en) | 1999-01-08 | 1999-01-08 | Improved immunogenic lhrh composition and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105543B true ZA200105543B (en) | 2003-01-22 |
Family
ID=3812278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105543A ZA200105543B (en) | 1999-01-08 | 2001-07-05 | Improved saponin adjuvant compositions and methods relating thereto. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9579379B1 (enExample) |
| EP (2) | EP1140165B1 (enExample) |
| JP (2) | JP4949555B2 (enExample) |
| AT (1) | ATE410183T1 (enExample) |
| AU (2) | AUPP807399A0 (enExample) |
| CA (2) | CA2660344A1 (enExample) |
| CY (1) | CY1108693T1 (enExample) |
| DE (1) | DE69939706D1 (enExample) |
| DK (1) | DK1140165T3 (enExample) |
| ES (1) | ES2317708T3 (enExample) |
| NZ (1) | NZ512011A (enExample) |
| PT (1) | PT1140165E (enExample) |
| TW (1) | TW533079B (enExample) |
| WO (1) | WO2000041720A1 (enExample) |
| ZA (1) | ZA200105543B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1150710B1 (en) | 1999-02-17 | 2010-04-21 | Csl Limited | Immunogenic complexes and methods relating thereto |
| GB0008877D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
| GB0008879D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
| WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
| KR20100018029A (ko) * | 2004-07-18 | 2010-02-16 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제 |
| BRPI0611390A2 (pt) * | 2005-06-01 | 2010-09-08 | Pfizer Prod Inc | composições de vacina e uso de composições compreendendo vacina anti-lhrh na preparação de um medicamento para tratar incontinência urinária |
| WO2008110912A1 (en) * | 2007-03-14 | 2008-09-18 | Pfizer Inc. | Fertility regulation in horses |
| EP2865389A1 (en) | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | IgE CH3 peptide vaccine |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| WO2011077309A2 (en) | 2009-12-22 | 2011-06-30 | Pfizer Vaccines Llc | Vaccine compositions |
| EP2576613A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Inc. | Her-2 peptides and vaccines |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
| KR20200040899A (ko) * | 2011-05-13 | 2020-04-20 | 조에티스 서비시즈 엘엘씨 | 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물 |
| CA2845884A1 (en) | 2011-08-22 | 2013-02-28 | Cangene Corporation | Clostridium difficile antibodies |
| EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| JP6431920B2 (ja) | 2013-09-17 | 2018-11-28 | オービーアイ ファーマ，インコーポレイテッド | 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 |
| WO2015042423A2 (en) | 2013-09-19 | 2015-03-26 | Zoetis Llc | Vaccine |
| KR20160077214A (ko) | 2013-12-16 | 2016-07-01 | 조에티스 서비시즈 엘엘씨 | 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20220080201A (ko) | 2014-01-21 | 2022-06-14 | 화이자 인코포레이티드 | 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
| CA2939572A1 (en) | 2014-02-19 | 2015-08-27 | Jody Berry | Marburg monoclonal antibodies |
| SG11201607258SA (en) | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
| DK3244917T5 (da) | 2015-01-15 | 2024-10-14 | Pfizer | Immunogene sammensætninger til anvendelse i pneumokokvacciner |
| ES2950822T3 (es) * | 2015-01-16 | 2023-10-13 | Zoetis Services Llc | Vacuna contra la enfermedad de fiebre aftosa |
| JP2018521016A (ja) | 2015-06-03 | 2018-08-02 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | ＩＬ−２３−ｐ１９ワクチン |
| US20180186896A1 (en) | 2015-07-07 | 2018-07-05 | Affiris Ag | Vaccines for the treatment and prevention of ige mediated diseases |
| KR102800419B1 (ko) | 2015-07-21 | 2025-04-25 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| EP3307322B1 (en) | 2015-09-04 | 2021-02-17 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| MY200886A (en) | 2016-04-22 | 2024-01-22 | Obi Pharma Inc | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens |
| JP2019527690A (ja) | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
| TWI767959B (zh) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| MX392525B (es) | 2017-01-20 | 2025-03-12 | Pfizer | Composiciones inmunogenicas para su uso en vacunas neumococicas |
| WO2019173438A1 (en) | 2018-03-06 | 2019-09-12 | Stc. Unm | Compositions and methods for reducing serum triglycerides |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3849521A1 (en) | 2018-09-14 | 2021-07-21 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
| WO2020121159A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| US11419932B2 (en) | 2019-01-24 | 2022-08-23 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
| CN109663126A (zh) * | 2019-03-01 | 2019-04-23 | 龙阔（苏州）生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN112516325B (zh) * | 2019-09-18 | 2023-12-08 | 洛阳赛威生物科技有限公司 | 一种稳定的口蹄疫疫苗组合物及其应用 |
| MX2022005252A (es) | 2019-11-01 | 2022-06-08 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| CA3173729A1 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN113967252B (zh) * | 2020-07-24 | 2024-03-26 | 洛阳赛威生物科技有限公司 | 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| TW202227467A (zh) | 2020-10-27 | 2022-07-16 | 美商輝瑞大藥廠 | 大腸桿菌組合物及其方法 |
| EP4240410A1 (en) | 2020-11-04 | 2023-09-13 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
| US20230190920A1 (en) | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
| EP4479088A1 (en) | 2022-02-14 | 2024-12-25 | University of Georgia Research Foundation, Inc. | Pan-pneumovirus vaccine compositions and methods of use thereof |
| AU2024296166A1 (en) * | 2023-07-07 | 2025-09-25 | Ouro Fino Saúde Animal Ltda | Modified gnrh peptide and its conjugate for mammalian immunocastration, manufacturing method, composition and kit |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1924304C3 (de) * | 1969-05-13 | 1980-07-17 | Bayer Ag, 5090 Leverkusen | Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren |
| DE3411224A1 (de) | 1984-03-27 | 1985-10-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren |
| DK166762B1 (da) * | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
| NZ221306A (en) | 1986-08-15 | 1990-02-26 | Commw Scient Ind Res Org | 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof |
| AU602187B2 (en) * | 1987-01-14 | 1990-10-04 | Commonwealth Scientific And Industrial Research Organisation | Anti-reproductive hormone |
| GB8707398D0 (en) * | 1987-03-27 | 1987-04-29 | Coopers Animal Health | Biologically active molecules |
| US4892830A (en) * | 1987-04-02 | 1990-01-09 | Baylor College Of Medicine | Environmentally controlled in vitro incubator |
| GB2228262B (en) | 1989-01-25 | 1992-10-07 | Nat Inst Immunology | Antigenic derivative of gnrh |
| AU5186090A (en) | 1989-02-23 | 1990-09-26 | Colorado State University Research Foundation | Gnrh analogs for destroying gonadotrophs |
| CA2040441C (en) * | 1989-08-25 | 1998-03-31 | Gregory J. Russell-Jones | Fusion proteins |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| GB8919819D0 (en) * | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| GB8921470D0 (en) * | 1989-09-22 | 1989-11-08 | Peptide Technology Ltd | Vaccines |
| US5324512A (en) | 1990-12-26 | 1994-06-28 | The Population Council | [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses |
| US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
| ZA934199B (en) | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
| US5650398A (en) * | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| US5614487A (en) | 1993-05-28 | 1997-03-25 | Genentech, Inc. | Sustained release pharmaceutical composition |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| AU7468196A (en) | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Conjugates of gonadotropin releasing hormone |
| AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| AUPO776897A0 (en) * | 1997-07-09 | 1997-07-31 | Csl Limited | A method of achieving production gains in livestock and agents useful for same |
| US6013770A (en) | 1997-07-21 | 2000-01-11 | Washington State University | Chimeric contraceptive vaccines |
| AUPP060097A0 (en) * | 1997-11-28 | 1998-01-08 | Commonwealth Scientific And Industrial Research Organisation | Adjuvant system for enhanced response |
-
1999
- 1999-01-08 AU AUPP8073A patent/AUPP807399A0/en not_active Abandoned
- 1999-12-24 CA CA002660344A patent/CA2660344A1/en not_active Abandoned
- 1999-12-24 CA CA2359111A patent/CA2359111C/en not_active Expired - Lifetime
- 1999-12-24 PT PT99968288T patent/PT1140165E/pt unknown
- 1999-12-24 ES ES99968288T patent/ES2317708T3/es not_active Expired - Lifetime
- 1999-12-24 EP EP99968288A patent/EP1140165B1/en not_active Expired - Lifetime
- 1999-12-24 EP EP08005701A patent/EP1946773A3/en not_active Withdrawn
- 1999-12-24 DE DE69939706T patent/DE69939706D1/de not_active Expired - Lifetime
- 1999-12-24 DK DK99968288T patent/DK1140165T3/da active
- 1999-12-24 AT AT99968288T patent/ATE410183T1/de active
- 1999-12-24 US US09/857,797 patent/US9579379B1/en not_active Expired - Fee Related
- 1999-12-24 AU AU25263/00A patent/AU758133B2/en not_active Expired
- 1999-12-24 NZ NZ512011A patent/NZ512011A/xx not_active IP Right Cessation
- 1999-12-24 WO PCT/AU1999/001167 patent/WO2000041720A1/en not_active Ceased
- 1999-12-24 JP JP2000593330A patent/JP4949555B2/ja not_active Expired - Lifetime
- 1999-12-27 TW TW088123010A patent/TW533079B/zh not_active IP Right Cessation
-
2001
- 2001-07-05 ZA ZA200105543A patent/ZA200105543B/en unknown
-
2009
- 2009-01-07 CY CY20091100002T patent/CY1108693T1/el unknown
-
2011
- 2011-11-04 JP JP2011242133A patent/JP2012072157A/ja active Pending
-
2012
- 2012-03-14 US US13/420,082 patent/US9149520B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69939706D1 (de) | 2008-11-20 |
| CA2359111A1 (en) | 2000-07-20 |
| CY1108693T1 (el) | 2012-05-23 |
| US20120251566A1 (en) | 2012-10-04 |
| JP2012072157A (ja) | 2012-04-12 |
| TW533079B (en) | 2003-05-21 |
| AUPP807399A0 (en) | 1999-02-04 |
| CA2359111C (en) | 2014-02-18 |
| WO2000041720A8 (en) | 2000-11-09 |
| EP1946773A2 (en) | 2008-07-23 |
| ES2317708T3 (es) | 2009-04-16 |
| AU2526300A (en) | 2000-08-01 |
| NZ512011A (en) | 2002-12-20 |
| JP2002534480A (ja) | 2002-10-15 |
| WO2000041720A1 (en) | 2000-07-20 |
| EP1140165B1 (en) | 2008-10-08 |
| JP4949555B2 (ja) | 2012-06-13 |
| EP1946773A3 (en) | 2008-07-30 |
| US9579379B1 (en) | 2017-02-28 |
| US9149520B2 (en) | 2015-10-06 |
| PT1140165E (pt) | 2009-01-13 |
| AU758133B2 (en) | 2003-03-13 |
| ATE410183T1 (de) | 2008-10-15 |
| CA2660344A1 (en) | 2000-07-20 |
| EP1140165A1 (en) | 2001-10-10 |
| EP1140165A4 (en) | 2005-01-05 |
| DK1140165T3 (da) | 2009-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200105543B (en) | Improved saponin adjuvant compositions and methods relating thereto. | |
| US8741303B2 (en) | Immunogenic LHRH compositions and methods relating thereto | |
| EP0464124B1 (en) | A peptide, immunogenic composition and vaccine or medicinal preparation; a method of immunising a mammal against lhrh, and a method of improving the meat quality of pigs | |
| US20040213817A1 (en) | Vaccine compositions and adjuvant | |
| US20050239701A1 (en) | Transient and/or permanent modification of sexual behavior and/or fertility using recombinant chimeric GnRH | |
| WO2008110912A1 (en) | Fertility regulation in horses | |
| Turkstra et al. | Active immunisation against gonadotropin-releasing hormone, an active tool to block the fertility axis in mammals | |
| WO2001034192A2 (en) | Improved method of immunization | |
| AU2006253914A1 (en) | Vaccine compositions and methods for the treatment of urinary incontinence |